healthEuropean Medicines Agency Backs Expanded Adolescent Use for Imvanex Mpox Vaccine
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the marketing authorization of Bavarian Nordic's Imvanex vaccine to protect adolescents aged 12 to 17 against smallpox and mpox amid global Clade Ib preparedness efforts.